MedTrace Logo

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT07220616 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-05-08

No results posted yet for this study

Summary

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Conditions

Interventions

DRUG

DS3790a

Administered as specified in the protocol

DRUG

Combination drug

Administered as specified in the protocol

DRUG

Combination drug

Administered as specified in the protocol

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-16
Primary Completion
2030-11-30
Completion
2030-11-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07220616 on ClinicalTrials.gov